Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Proteinuria 1Neoplasms 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 116Bevacizumab 102Capecitabine 100Oxaliplatin 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 85pembrolizumab 77Specimen Handling 77toripalimab 70Magnetic Resonance Spectroscopy 63Injections 63Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 51fludarabine 47Standard of Care 45Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43venetoclax 42Leucovorin 42lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × sparsentan × Clear all
NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Brigham and Women's Hospital

Phase 1 Not yet recruiting
20 enrolled

Neoplasms, Proteinuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡